Cell-permeable. A teratogen and sedative-hypnotic with inherent anti-inflammatory properties. A selective inhibitor of tumor necrosis factor a (TNF-a) synthesis. Thalidomide initiates its teratogenic effects by binding to cereblon (CRBN), a thalidomide-binding protein, and inhibiting the associated ubiquitin ligase activity. Classified as immunomodulatory drug, thalidomide suppresses the expression of tumor necrosis factor-alpha (TNF-i), interferes with a cascade of pro-inflammatory cytokines, and interferes with the secretion of vascular endothelial growth factor (VEGF) and beta fibroblast growth factor (bFGF). Similarly to apremilast, thalidomide carries a phthalimide ring, together with a glutarimide ring that is specifically recognized by the target molecule cereblon. Thanks to its ability to contrast neoangiogenesis and the modifications of the bone marrow stromal microenvironment, thalidomide is a powerful tool to fight hematologic cancers. In the treatment of SARS-CoV-2, the immunomodulatory and anti-inflammatory action of thalidomide has and has proved beneficial when combined with a low-dose glucocorticoid. Synonyms: 2-(2,6-Dioxopiperidin-3-yl)isoindoline-1,3-dione, ()-2-(2,6-Dioxopiperidin-3-yl)isoindoline-1,3-dione CAS No: 50-35-1 Molecular Formula: C13H10N2O4 Molecular Weight: 258.23 Purity (HPLC): 98% Appearance: White to grey powder Solubility: DMSO (~10mg/ml) Melting Point: 269-271C (lit) Storage and Stability: May be stored at RT for short-term only. Long-term storage is recommended at 4C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Molecular Weight:
258.23
CAS Number:
[50-35-1]
* VAT and and shipping costs not included. Errors and price changes excepted
